SCHEMBL4499247

SCHEMBL4499247

c1ccc2c(c1)[nH]c1[nH]c3ccccc3c12

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.60
GPR3 P46089 2/20 0.60
HSD17B10 Q99714 2/20 0.60
IMPDH2 P12268 1/20 0.52
IMPDH1 P20839 1/20 0.52
KMT2A Q03164 4/20 0.50
KDM4E B2RXH2 4/20 0.50
GABRP O00591 3/20 0.50
GABRD O14764 3/20 0.50
GABRA1 P14867 3/20 0.50
GABRB1 P18505 3/20 0.50
GABRG2 P18507 3/20 0.50
GABRB3 P28472 3/20 0.50
GABRA5 P31644 3/20 0.50
GABRA3 P34903 3/20 0.50
GABRA2 P47869 3/20 0.50
GABRB2 P47870 3/20 0.50
GABRA4 P48169 3/20 0.50
GABRE P78334 3/20 0.50
GABRA6 Q16445 3/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11647789 0.85 PARP1 (0.61) ALDH1A1GPR3HSD17B10KMT2AKDM4E
SCHEMBL11981337 0.84 KDM4E (0.64) ALDH1A1GPR3HSD17B10KMT2AKDM4E
SCHEMBL11981427 0.84 ALDH1A1 (0.50) ALDH1A1GPR3HSD17B10IMPDH2IMPDH1
SCHEMBL24425573 0.82 GABRP (0.49) ALDH1A1GPR3HSD17B10KMT2AKDM4E
SCHEMBL20712203 0.82 CCNB2 (0.59) ALDH1A1GPR3HSD17B10KMT2AGABRP
SCHEMBL24425669 0.82 CCNE2 (0.60) ALDH1A1KMT2AKDM4EGABRPGABRD
SCHEMBL15131696 0.80 KDM4E (0.67) ALDH1A1GPR3HSD17B10KMT2AKDM4E
SCHEMBL1635466 0.78 ALDH1A1 (0.68) ALDH1A1GPR3HSD17B10IMPDH2IMPDH1
SCHEMBL30741432 0.78 CHEK1 (0.65) ALDH1A1GPR3HSD17B10IMPDH2IMPDH1
SCHEMBL29380761 0.78 ALDH1A1 (0.68) ALDH1A1GPR3HSD17B10IMPDH2IMPDH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12479861-B2 Organic electroluminescent materials and devices UNIVERSAL DISPLAY CORPORATION (US) 2025-11-25 US claimed
US-20240246999-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES UNIVERSAL DISPLAY CORPORATION (US) 2024-07-25 US claimed
US-11716899-B2 Organic electroluminescent materials and devices UNIVERSAL DISPLAY CORPORATION (US) 2023-08-01 US claimed
US-20210210700-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES UNIVERSAL DISPLAY CORPORATION (US) 2021-07-08 US claimed
US-20260062424-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES UNIV DISPLAY CORPORATION (US) 2026-03-05 US disclosed
US-12479861-B2 Organic electroluminescent materials and devices UNIVERSAL DISPLAY CORPORATION (US) 2025-11-25 US disclosed
CN-112707923-B Organic electroluminescent material and device 环球展览公司 2025-06-03 CN disclosed
US-20240246999-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES UNIVERSAL DISPLAY CORPORATION (US) 2024-07-25 US disclosed
US-11919914-B2 Organic electroluminescent materials and devices UNIVERSAL DISPLAY CORPORATION (US) 2024-03-05 US disclosed
US-11825744-B2 Organic electroluminescence device and condensed cyclic compound for organic electroluminescence device SAMSUNG DISPLAY CO., LTD. (KR) 2023-11-21 US disclosed
US-11716899-B2 Organic electroluminescent materials and devices UNIVERSAL DISPLAY CORPORATION (US) 2023-08-01 US disclosed
US-20230006146-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES UNIVERSAL DISPLAY CORPORATION 2023-01-05 US disclosed
EP-1331010-A1 PREVENTIVES AND REMEDIES FOR CENTRAL NERVOUS SYSTEM DISEASES Takeda Chemical Industries, Ltd. (JP) 2003-07-30 EP disclosed
EP-1310490-A1 GPR14 ANTAGONIST Takeda Chemical Industries, Ltd. (JP) 2003-05-14 EP disclosed
EP-1308513-A1 USE OF POLYPEPTIDE Takeda Chemical Industries, Ltd. (JP) 2003-05-07 EP disclosed
US-6534496-B1 Prophylactic and/or therapeutic drug for obesity and obesity associated diseasestor diabetes with a reduced risk for central side effects and high universality in usage. Another object of the a lipolytic agent, or a prophylactic and/or TAKEDA CHEMICAL INDUSTRIES, INC. (JP) 2003-03-18 US disclosed
US-20020177593-A1 Agents and crystals for improving excretory potency of urinary bladder TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2002-11-28 US disclosed
EP-1118322-A1 DRUGS FOR IMPROVING VESICAL EXCRETORY STRENGTH Takeda Chemical Industries, Ltd. (JP) 2001-07-25 EP disclosed
US-5620973-A CHOLINESTERASE INHIBITOR; ALZHEIMER*S DISEASE TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1997-04-15 US disclosed
EP-0655451-A1 Tetracyclic condensed heterocyclic compounds for the treatment of senile dementia TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1995-05-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260062424-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES LBR, SIGMAR1, OXSR1 ALDH1A1 3447/4885GPR3 534/4885HSD17B10 3357/4885
US-20020177593-A1 Agents and crystals for improving excretory potency of urinary bladder ACHE, BPHL, BCHE ALDH1A1 1185/4885GPR3 1696/4885HSD17B10 3205/4885
US-11919914-B2 Organic electroluminescent materials and devices OCIAD2, OCIAD1, OSBP ALDH1A1 939/4885GPR3 1688/4885HSD17B10 1484/4885
US-20240246999-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES OCIAD2, OCIAD1, OSBP ALDH1A1 939/4885GPR3 1688/4885HSD17B10 1484/4885
US-11825744-B2 Organic electroluminescence device and condensed cyclic compound for organic electroluminescence device PIEZO1, OCIAD1, AQP1 ALDH1A1 131/4885GPR3 4041/4885HSD17B10 2110/4885
US-20230006146-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES OSBP, OCIAD2, OCIAD1 ALDH1A1 1842/4885GPR3 2556/4885HSD17B10 2762/4885
US-12479861-B2 Organic electroluminescent materials and devices OCIAD2, OCIAD1, OSBP ALDH1A1 939/4885GPR3 1688/4885HSD17B10 1484/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.